Contrast-enhanced magnetic resonance imaging (MRI) of focal liver lesions is typically performed with either extracellular or hepatobiliary-specific contrast agents. Although intravascular contrast agents are often used in contrastenhanced ultrasound imaging of focal liver lesions, these agents are not typically used for MR imaging [1] .
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Preliminary results show that MRI with intravascular (or blood-pool) contrast agents such as gadofosveset trisodium may be useful in characterisation of lesions in some situations [2, 3] . Gadofosveset trisodium is an intravascular contrast agent that reversibly binds to albumin and is Food and Drug Administrationeapproved for use in MRI vascular imaging, but is not routinely used for imaging liver lesions [4] .
The current literature on the use of gadofosvesetenhanced MRI for imaging focal liver lesions is limited. In fact, the appearances of only 5 types of solid hepatic lesions (hemangioma, adenoma, focal nodular hyperplasia (FNH), breast metastases, and colorectal metastases) using gadofosveset-enhanced MRI have been previously reported in the literature [2] . One additional study has described the appearances of cysts and metastases for contrast-enhanced MRI with a combined injection of gadoxetic acid and gadofosveset trisodium [3] .
This pictorial essay highlights a case series of benign and malignant (primary and secondary) focal liver lesions using gadofosveset-enhanced MRI, including some types of lesions (hepatocellular carcinoma [HCC], cholangiocarcinoma, and metastases from pancreatic adenocarcinoma, renal cell carcinoma, and neuroendocrine tumours) that have never been previously reported in the literature.
Methods
We are conducting a prospective study on the use of gadofosveset-enhanced MRI of the liver at our institution. This study has been approved by the institutional research ethics board and by Health Canada. This pictorial essay includes some of the patients from this study.
Patients who are referred for a clinical MRI of the liver for assessment of a focal liver lesion were eligible for the study. Patients received the standard clinical MRI with either gadobutrol or gadoxetate. They then received a second research MRI with gadofosveset performed on a separate day.
The gadofosveset-enhanced MRI protocol that was used includes axial T1 precontrast, arterial phase, portal venous phase, 5-minute delayed phase, and 10-minute delayed phase imaging. All studies were performed on either a 1.5-T (GE Twinspeed, Milwaukee, WI) or 3.0-T (Philips Achieva, Amsterdam, The Netherlands) magnets with an 8-channel body phased array coil utilised covering the entire liver. Patients received a standard 10 mL dose of gadofosveset trisodium at 0.25 mmol/mL.
Final diagnoses of lesions were determined as follows: pathology-confirmation based on surgery (cholangiocarcinoma, colorectal metastasis), pathology-confirmation based on biopsy of liver lesion (adenoma, neuroendocrine metastasis), pathologyconfirmation of primary cancer and typical appearance of liver metastasis on gadobutrol-enhanced MRI (metastases from pancreatic adenocarcinoma, breast carcinoma, and renal cell carcinoma), classic appearance with gadobutrol-enhanced MRI (HCC, hemangioma), and classic appearance with gadobutrolenhanced MRI and confirmation with gadoxetate-enhanced MRI (FNH). 
Benign Lesions
Hemangioma Cavernous hepatic hemangiomas are the most the common type of benign, solid tumour in the liver [5] . They are composed of multiple vascular channels [5] . With extracellular contrast agents, hemangiomas demonstrate early peripheral, discontinuous enhancement on arterial phase imaging with progressive fill-in on subsequent portal venous and delayed phases [5] . As seen in Figure 1 , this hemangioma has the same enhancement pattern with gadofosveset as is typical with extracellular contrast agents.
Focal Nodular Hyperplasia
FNHs are benign tumours thought to be due to a hyperplastic response to congenital vascular anomalies [5] . With extracellular contrast agents, FNHs demonstrate homogeneous arterial enhancement that subsequently becomes isointense to background liver on portal venous and delayed phases [5] . They can have a central scar is typically hypoenhancing in arterial phase, but may demonstrate enhancement on delayed phases [5] . As seen in Figure 2 , this FNH has the same enhancement pattern with gadofosveset as is typical with extracellular contrast agents.
Adenoma
Hepatic adenomas are rare, benign tumours arising from hepatocytes [5] . Their appearance depends on their subtype as well as the presence of hemorrhage or fat within the tumour. The hepatic adenoma in Figure 3 is slightly hyperenhancing on arterial phase and slightly hypoenhancing on delayed phase using MRI with gadofosveset. This enhancement pattern is similar to the appearance typical with extracellular contrast agents [5] .
Primary Malignant Lesions

Hepatocellular Carcinoma
HCC is a primary liver malignancy arising from hepatocytes [5] . It is the most common primary liver malignancy. With gadofosveset-enhanced MRI, the HCC in Figure 4 demonstrates arterial enhancement with washout on portal venous and delayed phases. There is evidence of a capsule. This appearance is similar to the typical enhancement pattern seen with extracellular contrast agents [5] .
Cholangiocarcinoma
Intrahepatic cholangiocarcinoma is a primary liver malignancy arising from bile ducts [6] . Gadofosveset-enhanced MRI shows an infiltrating mass that is rim-enhancing on arterial phase with progressive centripetal filling and central enhancement on delayed phase ( Figure 5, A and B) [6] . This is associated with capsular retraction [6] . We note that the degree of central enhancement on delayed phase imaging is less pronounced with gadofosveset ( Figure 5B ) than with gadobutrol ( Figure 5C ).
Secondary Malignant Lesions
Colorectal Metastases
Colorectal liver metastases are generally considered hypovascular metastases [7] . Classic features of colorectal liver metastases with extracellular contrast agents include rim-enhancement on arterial phase and peripheral washout on delayed phases [7] . With extracellular contrast agents, some metastases can demonstrate some delayed enhancement centrally [7] . Using gadofosveset-enhanced MRI, features of rim-enhancement and peripheral washout appear to be similar to appearances with extracellular contrast agents ( Figure 6, A and B) . In this patient, the degree of central enhancement on delayed phase imaging appears less pronounced with gadofosveset ( Figure 6B ) than with gadobutrol ( Figure 6C) . Although no mechanistic studies have been performed to date, it has been hypothesized the diffusion of contrast into the interstitium during the extravascular phase with gadobutrol may not be as pronounced with gadofosveset due to its intravascular properties [2] .
Pancreatic Adenocarcinoma Metastases
Hepatic metastases from pancreatic adenocarcinoma are also considered hypovascular metastases [8] . In (Figure 7, A and B) , this metastasis from pancreatic adenocarcinoma demonstrates rim-enhancement on arterial phase with gadofosveset-enhanced MRI and is similar in appearance to the typical appearances with extracellular contrast agents ( Figure 7C ) [8] . 
Breast Metastases
The vascularity of breast metastases can vary, although they are often considered to hypervascular metastases [8] . With gadofosveset-enhanced MRI, multiple breast metastases from this patient show continuous rim enhancement on arterial phase with persistent enhancement on delayed phases ( Figure 8, A and B) . We note that the degree of perisistent enhancement on delayed phase image in this patient is less pronounced with gadofosveset ( Figure 8B ) than with gadobutrol ( Figure 8C ).
Renal Cell Metastases
Liver metastases from renal cell carcinoma are generally considered hypervascular metastases [5] . With gadofosvesetenhanced MRI, this renal cell carcinoma demonstrates arterial enhancement that persists in the delayed phase ( Figure 9, A and B) . The appearance with gadofosvesetenhanced MRI is similar to that with gadobutrol-enhanced MRI ( Figure 9C ) [5] .
Neuroendocrine Metastases
Neuroendocrine liver metastases are hypervascular metastases [5] . With gadofosveset-enhanced MRI, the lesions in this patient are arterially enhancing with increasing enhancement on delayed phase imaging ( Figure 10, A and B ) [5] . Although the pattern of enhancement is similar to that of extracellular contrast agents, there appears to be more pronounced enhancement of neuroendocrine metastases on delayed phase imaging with gadofosveset ( Figure 10B ) than with gadobutrol ( Figure 10C ) in this patient. Some neuroendocrine metastases contain vascular channels [9] . Given that gadofosveset is an intravascular contrast agent, we would expect a greater degree of enhancement with gadofosveset than with gadobutrol in tumours rich with vascular channels.
Conclusion
Some studies have suggested that the use of intravascular contrast agents such as gadofosveset for MR imaging of focal liver lesions may have utility in some situations either Figure 10 . Multiple liver metastases from a carcinoid tumour with gadofosveset-enhanced magnetic resonance imaging (MRI) in the (A) arterial and (B) 10minute delayed phase imaging and with gadobutrol-enhanced MRI in (C) 10-minute delayed phase imaging. There is arterial enhancement with persistent enhancement in delayed phase imaging. Note that there is a greater degree of enhancement on delayed phase imaging with gadofosveset than with gadobutrol. alone or in combination with hepatobiliary-specific contrast agents [2, 3] . However, literature in this area is limited. This pictorial essay aims to provide a case series of the appearance of several types of common benign and malignant focal liver lesions using gadofosveset-enhanced MRI. However, large-scale studies are required to determine the range of appearances of different focal liver lesions as well as to clarify and define the role of gadofosveset-enhanced MR imaging for focal liver lesions.
